Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Kosuke Takemura, Daniel Yick Chin Heng, Lori Wood et al.|Journal of Clinical Oncology|2023Cited by 4
Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Rana R. McKay, Jiaming Huang et al.|Cancer|2024Cited by 3
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.Chris Labaki, Toni K. Choueiri, Ziad Bakouny et al.|Journal of Clinical Oncology|2023Cited by 1
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Georges Gebrael, Toni K. Choueiri, Neeraj Agarwal et al.|Journal of Clinical Oncology|2023Cited by 0